3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
18
Thoracic
5
Genitourinary
5
Dermatologic
4
Gastrointestinal
3
Gynecologic
2
Breast
2
Other solid neoplasm
1
Lymphoid
1
Conditions
Mesothelioma
21
Mesothelioma, Malignant
18
Advanced Solid Tumor
17
Carcinoma, Non-Small-Cell Lung
15
Solid Tumor
14
Advanced Solid Tumors
13
Melanoma
12
Esophageal Neoplasms
10
Carcinoma, Renal Cell
10
Stomach Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
9
Uterine Cervical Neoplasms
8
Solid Tumors
8
Ovarian Neoplasms
8
Solid Tumor, Adult
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
6
Small Cell Lung Carcinoma
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
5
Endometrial Neoplasms
5
Cholangiocarcinoma
5
Neoplasms
4
Locally Advanced or Metastatic Solid Tumors
4
Head and Neck Neoplasms
4
Advanced or Metastatic Solid Tumors
4
Urinary Bladder Neoplasms
3
Solid Tumor Malignancies
3
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oropharyngeal Neoplasms
×
pembrolizumab
×
Other solid neoplasm
×
Clear all
NCT04301011
2025-04-23
RAPTOR
Turnstone Biologics, Corp.
Phase 1
Terminated
27 enrolled